KRONİK HEPATİT B VE B+D KAYNAKLI SİROZDA, HEPATOSELÜLER KARSİNOM GELİŞİMİNİN ÖNGÖRÜLMESİNDE ALBI VE PALBI SKORLAMALARININ PREDİKTİF DEĞERİ

Amaç:Hepatosellüler karsinom (HCC), dünya çapında kanser kaynaklı ölümlerin ikinci en sık nedenidir. Bu nedenle, HCC’de erken tanı çok önemlidir. Bu çalışmanın amacı, sirozlu hastalarda HCC gelişiminde albumin-bilirubin indeksi (ALBI) ve Platelet- albumin-bilirubin indeksinin (PALBI) prediktivitelerinin değerlendirilmesidir. Materyal ve Metot:Çalışmaya 2004-2019 yılları arasında Demiroğlu Bilim Üniversitesi'ne başvuran kronik hepatit B ve kronik hepatit B + D ‘ ye bağlı karaciğer sirozlu 331 hasta dahil edildi. Hastalar HCC olan ve HCC olmayan olmak üzere iki ana gruba ayrıldı. Hastaların demografik verileri, vücut kitle indeksleri (VKİ), Child ve MELD skorları ve laboratuvar bulguları gruplar için ayrı ayrı kaydedildi ve analiz edildi. Her iki grup için ortalama ALBI ve PALBI değerleri hesaplandı. ALBI, PALBI ve HCC arasındaki ilişkilerdeğerlendirildi. Bulgular:Hastaların yaş ortalaması 51.3 ± 9.18, ortalama BKİ 30.04 ± 11.65 idi. HCC grubu 115 hastadan ve HCC olmayan siroz grubu 216 hastadan oluşmaktaydı. Ortalama ALBI ve PALBI skor değerleri, HCC grubunda HCC olmayan siroz grubuna göre anlamlı derecede düşüktü (p

The Predictive Value of ALBI and P-ALBI Scores in The Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis

Aim:Hepatocellular carcinoma (HCC) is the second most common cause of cancer related deaths worldwide. Therefore, early diagnosis is too important for HCC. The aim of this study was to evaluate the predictive value of albumin-bilirubin index (ALBI) and platelet-albumin-bilirubin index (PALBI) on the development of HCC in patients withcirrhosis. Materials and Methods:331 patients with liver cirrhosis due to chronic hepatitis B and chronic hepatitis B + D who were admitted to Demiroğlu Bilim University between 2004-2019 were included in the study. The patients were divided into two main groups, with and without HCC. Demographic data, body mass index (BMI), Child and MELD scores and laboratory findings of the patients were recorded and analyzed separately for the groups. Mean ALBI and PALBI values were calculated for both groups. The relationships between ALBI, PALBI and HCC wereevaluated. Results:The mean age of the patients was 51.3 ± 9.18 and, the mean BMI was 30.04 ± 11.65. The HCC group consisted of 115 patients and the non-HCC cirrhosis group consisted of 216 patients. Mean ALBI and PALBI score values were significantly lower in HCC group than in non-HCC cirrhosis group (p

PDF

___

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.
2. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015; 13:2140–51.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27 ,
4. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471–4.
5. Forner A, Reig ME, De Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1): 61–74.
6. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4):918–28.
7. Gallo C. Capuano G, Daniele B, Gaeta GB, Perrone F, Pignata S. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28(3):751–5.
8. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000; 32(6):1224–9.
9. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiologicalcharacteristics and disease burden. J Viral Hepat. 2009; 16(7):453–63.
10. Perz JF, Armstrong GL, Farrington LA, Huntin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol.2006;45(4):529-38.
11. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7(8): 448-58
12. Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944-54.
13. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol.2014;28(5):843-53.
14. Wang T, Liu M, Zheng SJ, Bian DD, Zhang JY, Yao J, et al. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein- negative hepatocellular carcinoma. World J Gastroenterol. 2017; 23(19): 3496-504.
15. Mathew S, Ali A, Abdel-Hafiz H, Fatima K, Suhail M, Archunan G, et al. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infect Genet Evol. 2014;26:327-39.
16. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-70.
17. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004; 40(6):897-903.
18. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006;12(7):1049-61.
19. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015 Feb20;33(6):550-8.
20. Chan AW, Kumada T, Toyoda H, Tada T, Chong CC, Mo FK, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016; 31(7):1300–6.
21. Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016; 31(5):1031–6.
22. Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, et al. PALBI - An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child’s Classification. In: The Liver Meeting. San Francisco, USA: American Association for the Study of Liver Diseases.2015.
23. Chan AW, Chong CC, Mo FK, Wong J, YeoW,Johnson PJ, et al. Applicability of albumin-bilirubin- based Japan integrated staging score in hepatitis B- associated hepatocellular carcinoma. J Gastroenterol Hepatol.2016;31(10):1766-72.
24. LiMX,Zhao H, Bi XY, Li ZY, Huang Z, Han Y, et al. Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatology Research. 2017; 47(8): 731–41.
25. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
26. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127(5 Suppl1):S218–24.
27. Ho CHM, Chiang CL, Lee FAS, Choi HCW, Chan JCH, Yeung CSY, et al. Comparison of platelet- albumin-bilirubin (PALBI), albumin-bilirubin(ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). Oncotarget.2018;9(48): 28818-29.
28. Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology 2017; 32: 879–86.
29. Hansmann J, Evers MJ, Bui JT, Lokken RP, Lipnik AJ, Gaba RC, et al. Albumin-Bilirubin and Platelet- Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017 Sep;28(9):1224-31.
30. Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer.2017;6(3):204-15.
31. Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade:Anationwide cohort study. PLoS One.2019;14(5):e0216173.
32. Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, et al. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019; 51(10): 1430-7.
33. Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, et al. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol.2019;11(6):542-552.